文献速递系统性红斑狼疮

贝利尤单抗治疗系统性红斑狼疮:早期病程与低基线损伤预测应答

Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
PubMed 文献 · Arthritis Rheumatol · 2020-06-12

该多中心回顾性研究纳入意大利24个中心466例接受静脉贝利尤单抗的活动性SLE患者,中位随访18个月。结果显示,基线SLEDAI-2K≥10、病程≤2年及基线SDI为0与较好应答相关;随访中达缓解或低疾病活动时间比例较高者损伤累积更少。

要点

  • 基线SLEDAI-2K≥10与6、12、24、36个月SRI-4应答独立相关。
  • 病程≤2年及基线SDI为0是早期治疗应答的预测因素。
  • 缓解≥25%或低疾病活动≥50%随访期的患者损伤累积显著更少。

核心结论

  • 在活动性SLE且基线损伤低的患者中,疾病早期使用贝利尤单抗可能获得更有利的真实世界结局。

研究设计与样本

  • 多中心回顾性队列研究,纳入意大利24个中心466例接受静脉贝利尤单抗的活动性SLE患者,中位随访18个月(范围1-60个月)。
  • 采用SRI-4评估应答,SDI每年评分损伤,多因素logistic回归分析预测因素并以OR及95%CI表达。

主要发现

  • SRI-4应答率在6、12、24、36、48个月分别为49.2%、61.3%、69.7%、69.6%、66.7%。
  • 6个月应答预测因素包括基线SLEDAI-2K≥10(OR 3.14 [95%CI 2.033-4.860])和病程≤2年(OR 1.94 [95%CI 1.078-3.473)。
  • 12个月应答预测因素包括基线SLEDAI-2K≥10(OR 3.48 [95%CI 2.004-6.025])和SDI为0(OR 1.74 [95%CI 1.036-2.923])。
  • 24个月应答预测因素包括基线SLEDAI-2K≥10(OR 4.25 [95%CI 2.018-8.940])和病程≤2年(OR 3.79 [95%CI 1.039-13.52])。
  • 36个月应答预测因素包括基线SLEDAI-2K≥10(OR 14.59 [95%CI 3.54-59.79]),当前吸烟者为负相关(OR 0.19 [95%CI 0.039-0.69])。

关键数值与推荐

  • 随访中缓解≥25%者占44.3%、低疾病活动≥50%者占66.1%,其损伤累积显著更少(P=0.046和P=0.007)。
  • 基线SDI为0是达低疾病活动≥50%随访期及缓解≥25%随访期的独立预测因素。
  • 贝利尤单抗启用前 flare 次数与因无效停药频率呈负相关(P=0.009)。

临床怎么用

  • 对活动性SLE且基线损伤低、病程短的患者,可考虑尽早使用贝利尤单抗以争取更佳应答。
  • 基线SLEDAI-2K≥10提示较高应答概率,可作为治疗决策参考。
  • 当前吸烟与36个月应答负相关,治疗前应重视戒烟干预。

局限性

  • 为回顾性多中心队列研究,可能存在选择偏倚与混杂。
  • 随访时间不等(1-60个月),部分时间点事件数有限使OR置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab. METHODS: In this retrospective study of a multicenter cohort of SLE patients who received intravenous belimumab, the proportion of patients who achieved remission, low disease activity, and treatment response according to the SLE Responder Index 4 (SRI-4) was determined, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was used to score disease damage yearly over the follow-up. Predictors of outcomes were analyzed by multivariate logistic regression with the results expressed as odds ratios (ORs) and 95% confidence intervals (95% CIs). RESULTS: The study included 466 patients with active SLE from 24 Italian centers, with a median follow-up period of 18 months (range 1-60 months). An SRI-4 response was achieved by 49.2%, 61.3%, 69.7%, 69.6%, and 66.7% of patients at 6, 12, 24, 36, and 48 months, respectively. Baseline predictors of response at 6 months included a score of ≥10 on the SLE Disease Activity Index 2000 (SLEDAI-2K) (OR 3.14 [95% CI 2.033-4.860]) and a disease duration of ≤2 years (OR 1.94 [95% CI 1.078-3.473). Baseline predictors of response at 12 months included a score of ≥10 on the SLEDAI-2K (OR 3.48 [95% CI 2.004-6.025]) and an SDI score of 0 (OR 1.74 [95% CI 1.036-2.923]). Baseline predictors of response at 24 months included a score of ≥10 on the SLEDAI-2K (OR 4.25 [95% CI 2.018-8.940]) and a disease duration of ≤2 years (OR 3.79 [95% CI 1.039-13.52]). Baseline predictors of response at 36 months included a score of ≥10 on the SLEDAI-2K (OR 14.59 [95% CI 3.54-59.79) and baseline status of current smoker (OR 0.19 [95% CI 0.039-0.69]). Patients who were in remission for ≥25% of the follow-up period (44.3%) or who had low disease activity for ≥50% of the follow-up period (66.1%) accrued significantly less damage (P = 0.046 and P = 0.007). A baseline SDI score of 0 was an independent predictor of achieving low disease activity in ≥50% of the follow-up period and remission in ≥25% of the follow-up period. Our findings suggest that the lower the baseline damage, the greater the probability of achieving remission over the course of ≥25% of the follow-up. Further, there was a negative association between the number of flares reported prior to belimumab initiation and the frequency of belimumab discontinuation due to inefficacy (P = 0.009). CONCLUSION: In patients with active SLE and low damage at baseline, treatment with belimumab early in the disease may lead to favorable outcomes in a real-life setting.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gatto M, Saccon F, Zen M, et al. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Arthritis Rheumatol. 2020. PMID: 32275125. doi:10.1002/art.41253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。